Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;1860(1 Pt B):246-51.
doi: 10.1016/j.bbagen.2015.06.010. Epub 2015 Jul 2.

Alpha-crystallin-derived peptides as therapeutic chaperones

Affiliations
Review

Alpha-crystallin-derived peptides as therapeutic chaperones

Murugesan Raju et al. Biochim Biophys Acta. 2016 Jan.

Abstract

Background: The demonstration of chaperone-like activity in peptides (mini-chaperones) derived from α-crystallin's chaperone region has generated significant interest in exploring the therapeutic potential of peptide chaperones in diseases of protein aggregation. Recent studies in experimental animals show that mini-chaperones could reach intended targets and alter the disease phenotype. Although mini-chaperones show potential benefits against protein aggregation diseases, they do tend to form aggregates on storage. There is thus a need to fine-tune peptide chaperones to increase their solubility, pharmacokinetics, and biological efficacy.

Scope of review: This review summarizes the properties and the potential therapeutic roles of mini-chaperones in protein aggregation diseases and highlights some of the refinements needed to increase the stability and biological efficacy of mini-chaperones while maintaining or enhancing their chaperone-like activity against precipitation of unfolding proteins.

Major conclusions: Mini-chaperones suppress the aggregation of proteins, block amyloid fibril formation, stabilize mutant proteins, sequester metal ions, and exhibit antiapoptotic properties. Much work must be done to fine-tune mini-chaperones and increase their stability and biological efficacy. Peptide chaperones could have a great therapeutic value in diseases associated with protein aggregation and apoptosis.

General significance: Accumulation of misfolded proteins is a primary cause for many age-related diseases, including cataract, macular degeneration, and various neurological diseases. Stabilization of native proteins is a logical therapeutic approach for such diseases. Mini-chaperones, with their inherent antiaggregation and antiapoptotic properties, may represent an effective therapeutic molecule to prevent the cascade of protein conformational disorders. Future studies will further uncover the therapeutic potential of mini-chaperones. This article is part of a Special Issue entitled Crystallin Biochemistry in Health and Disease.

Keywords: Crystallins; Mini-chaperones; Peptide; Protein aggregation; Therapeutics.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The efficacy of mini-αA chaperone on αA66-80 peptide accelerated ADH aggregation. (1) ADH 150 μg. (2) ADH 150 μg and αA66-80 10 μg. (3) ADH 150 μg and αA66-80 10 μg and mini-αA 10 μg. (4) ADH 150 μg and αA66-80 10 μg and mini-αA 20 μg. (5) ADH 150 μg and αA66-80 10 μg and mini-αA 30 μg. (6) ADH 150 μg and mini-αA 10 μg. The chaperone activity was measured using the method described earlier [61]
Fig 2
Fig 2
Comparison of mini chaperone activities; synthesized with D-amino acid or L-amino acid. ADH aggregation assay was performed to test the efficacy of chaperone like function of mini chaperone’s L and D form. (1) ADH 50 μg. (2) ADH 50 μg and D-mini-αB 10 μg. (3) ADH 50 μg, L-mini-αB 10 μg. (4) ADH 50 μg, D-mini-αA 10 μg, (5) ADH 50 μg, L-mini-αA 10 μg. (6) ADH 50 μg, mixed D-mini-αB and D-mini-αA (1:1) 10 μg.

Similar articles

Cited by

References

    1. Sharma KK, Santhoshkumar P. Lens aging: effects of crystallins. Biochim Biophys Acta. 2009;1790:1095–1108. - PMC - PubMed
    1. Bloemendal H. Molecular and Cellular Biology of the Eye Lens. John Willey & Sons; New York: 1981. The lens proteins; pp. 1–49.
    1. Horwitz J. Alpha-crystallin. Exp Eye Res. 2003;76:145–153. - PubMed
    1. Bloemendal H, de Jong W, Jaenicke R, Lubsen NH, Slingsby C, Tardieu A. Ageing and vision: structure, stability and function of lens crystallins. Prog Biophys Mol Biol. 2004;86:407–485. - PubMed
    1. Horwitz J, Huang QL, Ding L, Bova MP. Lens alpha-crystallin: chaperone-like properties. Methods Enzymol. 1998;290:365–383. - PubMed

Publication types

MeSH terms